Logo

Lab21 Raises $3.2M in Private Round of Financing

Dec 23, 2008
NEW YORK (GenomeWeb News) – Diagnostics products and services firm Lab21 today said that it has raised £2.2 million ($3.2 million) from a round of financing with private equity investors.
 
The Cambridge, UK-based firm, which has diagnostics products and services focused on infectious diseases, oncology, and pharmacogenetics, said it would use the funds to further its acquisition plan and to establish its US operations in South Carolina with an eye toward expanding its North American presence.
 
Boston-based Nexus Medical Partners and UK-based Rowan Dartington participated in the round and join Merlin Biosciences and Kreos Capital as shareholders. As part of the investment, Ed Snape, co-founder and head of the healthcare practice for Nexus, will join the board of Lab21.
 
Lab21 expects to complete two acquisitions in Europe in the first half of 2009.
 
Among the firm’s diagnostic services offerings are molecular tests for cytochrome P450 and DxS’ KRAS assay.

Breaking News
The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.